Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Clinical Cancer Research2012Vol. 18(8), pp. 2402–2412
Citations Over TimeTop 10% of 2012 papers
Maggie C.U. Cheang, K. David Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen Chia, Lois E. Shepherd, Mark N. Levine, Kathleen I. Pritchard, Sherri R. Davies, Inge J. Stijleman, Carole Davis, Mark Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, Torsten O. Nielsen
Abstract
HER2-E strongly predicted anthracycline sensitivity. The chemotherapy-sensitive basal-like tumors showed no added benefit for CEF over CMF, suggesting that nonanthracycline regimens may be adequate in this subtype although further investigation is required.
Related Papers
- → Epirubicin: Is it like doxorubicin in breast cancer? A clinical review(2012)213 cited
- → Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin(1999)62 cited
- → The use of dexrazoxane as a cardioprotectant in patients receiving epirubicin-based chemotherapy for metastatic breast cancer(2005)1 cited
- [Acute pulmonary edema during general anesthesia in a young woman treated with epirubicin].(1995)
- Prospective Randomized Controlled Study of Cardiopretective Effect of Dexrazoxane on the Female Breast Cancer Patients with Postoperative Chemotherapy(2012)